It’s a complete merge with Generex owning and controlling the new company, NuGenerex immuno-oncology gets a great team to put around Eric and our science, we get 4 class A platform assets, with CAR T and oral delivery being high high potential winners as well as the Diamond AI technology and other red hot button winning areas.